{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:26:34Z","timestamp":1787945194568,"version":"build-2784847793"},"reference-count":41,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology","doi-asserted-by":"publisher","award":["2014R1A1A2A16055218"],"award-info":[{"award-number":["2014R1A1A2A16055218"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI15C1200"],"award-info":[{"award-number":["HI15C1200"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jacc.2018.05.066","type":"journal-article","created":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T14:06:07Z","timestamp":1534169167000},"page":"838-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Edoxaban in Asian Patients With Atrial\u00a0Fibrillation"],"prefix":"10.1016","volume":"72","author":[{"given":"So-Ryoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eue-Keun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Do","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seil","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.05.066_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50-year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.05.066_bib2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation","volume":"11","author":"Rahman","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2018.05.066_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijcard.2017.02.039","article-title":"Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population","volume":"236","author":"Lee","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.05.066_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1378\/chest.14-0321","article-title":"Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation","volume":"147","author":"Guo","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2018.05.066_bib5","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2018.05.066_bib6","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1160\/TH17-08-0555","article-title":"Regional differences in antithrombotic treatment for atrial fibrillation: insights from the GLORIA-AF Phase II Registry","volume":"117","author":"Mazurek","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2018.05.066_bib7","doi-asserted-by":"crossref","first-page":"e0189495","DOI":"10.1371\/journal.pone.0189495","article-title":"Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: a nationwide population-based study","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.05.066_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4070\/kcj.2017.0146","article-title":"A\u00a0prospective survey of atrial fibrillation management for real-world guideline adherence: Comparison study of drugs for symptom control and complication prevention of atrial fibrillation (CODE-AF) registry","volume":"47","author":"Kim","year":"2017","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacc.2018.05.066_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.4070\/kcj.2017.0362","article-title":"Prevalence of non-valvular atrial fibrillation based on geographical distribution and socioeconomic status in the entire Korean population","volume":"48","author":"Lee","year":"2018","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacc.2018.05.066_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.05.066_bib11","doi-asserted-by":"crossref","first-page":"i3189","DOI":"10.1136\/bmj.i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","author":"Larsen","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2018.05.066_bib12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","author":"Lip","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2018.05.066_bib13","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH17-01-0068","article-title":"Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in \u201creal-world\u201d clinical practice. A propensity-matched analysis of 76,940 patients","volume":"117","author":"Li","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2018.05.066_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/STROKEAHA.115.011476","article-title":"Cardiovascular, bleeding, and mortality risks of dabigatran in Asians with nonvalvular atrial fibrillation","volume":"47","author":"Chan","year":"2016","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2018.05.066_bib15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jacc.2016.06.062","article-title":"Thromboembolic, bleeding, and mortality risks of rivaroxaban and dabigatran in Asians with nonvalvular atrial fibrillation","volume":"68","author":"Chan","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.05.066_bib16","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1161\/STROKEAHA.117.018773","article-title":"Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation","volume":"48","author":"Cha","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2018.05.066_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/pds.4350","article-title":"Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study","volume":"27","author":"Potteg\u00e5rd","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacc.2018.05.066_bib18","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.05.066_bib19","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1161\/STROKEAHA.117.017114","article-title":"Warfarin use in patients with atrial fibrillation undergoing hemodialysis: a nationwide population-based study","volume":"48","author":"Yoon","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2018.05.066_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2018.05.066_bib21","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.05.066_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1161\/CIRCULATIONAHA.116.022361","article-title":"Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial","volume":"134","author":"Bohula","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.05.066_bib23","series-title":"Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference","article-title":"Reducing bias in a propensity score matched-pair sample using Greedy matching techniques","author":"Parsons","year":"2001"},{"key":"10.1016\/j.jacc.2018.05.066_bib24","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jama.286.10.1187","article-title":"Aspirin use and all-cause\u00a0mortality among patients being evaluated for\u00a0known or suspected coronary artery disease: a propensity analysis","volume":"286","author":"Gum","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2018.05.066_bib25","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2018.05.066_bib26","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jacc.2018.05.066_bib27","doi-asserted-by":"crossref","first-page":"e18174","DOI":"10.1371\/journal.pone.0018174","article-title":"Weight trimming and propensity score weighting","volume":"6","author":"Lee","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2018.05.066_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jacc.2018.05.066_bib29","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1161\/STROKEAHA.115.009947","article-title":"Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis","volume":"46","author":"Wang","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2018.05.066_bib30","unstructured":"US Food and Drug Administration. Prescribing information for Savaysa (edoxaban). 2015. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf. Accessed January 19, 2018."},{"key":"10.1016\/j.jacc.2018.05.066_bib31","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2018.05.066_bib32","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.05.066_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijcard.2016.08.236","article-title":"Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry","volume":"223","author":"Oh","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.05.066_bib34","doi-asserted-by":"crossref","first-page":"e000067","DOI":"10.1161\/JAHA.112.000067","article-title":"Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial","volume":"2","author":"Singer","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2018.05.066_bib35","first-page":"789","article-title":"Stroke prevention in atrial fibrillation: an Asian perspective","volume":"111","author":"Chiang","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2018.05.066_bib36","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2018.05.066_bib37","unstructured":"Lixiana: EPAR-product information. 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002629\/WC500189045.pdf. Accessed January 19, 2018."},{"key":"10.1016\/j.jacc.2018.05.066_bib38","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2018.05.066_bib39","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4070\/kcj.2017.0158","article-title":"Real-world data and recommended dosage of non-vitamin K oral anticoagulants for Korean patients","volume":"47","author":"Joung","year":"2017","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacc.2018.05.066_bib40","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2018.05.066_bib41","article-title":"Comparative effectiveness and safety of dabigatran and rivaroxaban in atrial fibrillation patients","volume":"6","author":"Lai","year":"2017","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718352884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109718352884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:15:38Z","timestamp":1760015738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718352884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0735109718352884"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.05.066","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edoxaban in Asian Patients With Atrial\u00a0Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.05.066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}